Novartis And Eisai End Co-promotion Of COPD Drugs
This article was originally published in PharmAsia News
Executive Summary
Novartis and Eisai ended their co-promotion agreement Dec. 31, 2012 for COPD drugs Onbrez and Seebri sold by Novartis and QVA149 – currently pending marketing approval – the companies announced.
Novartis and Eisai ended their co-promotion agreement Dec. 31, 2012 for COPD drugs Onbrez and Seebri sold by Novartis and QVA149 – currently pending marketing approval – the companies announced.During the agreement, Novartis was responsible for promotion at major hospitals and university hospitals, while Eisai promoted the drugs to general practitioners and general hospitals. Novartis will now handle all promotional activities and will add 1,600 primary care sales representatives to the reps already in charge of respiratory, infection, and transplant promotion. The companies signed a co-promotion contract in November 2011 to take advantage of the strengths of both companies in the respiratory field, but the agreement was terminated due to changes in Novartis’s sales strategy and changes in the market environment. (Click Here For More – Japanese Language)
“Novartis And Eisai End Co-Promotion Of COPD Drug” mixonline.jp 1/8/2013